Assembly Biosciences (ASMB) vs Capricor Therapeutics (CAPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Capricor Therapeutics (CAPR) has outperformed Assembly Biosciences (ASMB) over the past year, gaining 8.0% versus a loss of 3.8%. Over five years, CAPR leads with a +104.5% price change compared with -41.3% for ASMB. Capricor Therapeutics is the larger company by market cap ($465.7 million vs $453.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASMB | CAPR |
|---|---|---|
| Share price | $22.29 | $8.01 |
| Market cap | $453.84M | $465.69M |
| 1-day change | -2.88% | -1.11% |
| YTD return | -32.52% | -71.93% |
| 1-year return | -3.81% | +8.00% |
| 5-year return | -41.33% | +104.55% |
| P/E ratio (TTM) | 21.43 | — |
| EPS (TTM) | $1.04 | $-2.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.71 | $40.37 |
| 52-week low | $21.80 | $2.96 |
| Distance from 52-week high | -43.87% | -80.16% |
| Analyst consensus | none | buy |
| Avg. price target upside | +133.29% | +237.08% |
| Average volume | 278.07K | 6.85M |
| Shares outstanding | 20.36M | 58.14M |
| Employees | 73 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAPR has outperformed ASMB by 11.8 percentage points over the past year.
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
ASMB vs CAPR FAQ
Which is bigger, Assembly Biosciences or Capricor Therapeutics?
Capricor Therapeutics (CAPR) is larger, with a market capitalization of $465.69M compared with $453.84M for Assembly Biosciences (ASMB).
Which stock has performed better over the past year, ASMB or CAPR?
CAPR returned +8.00% over the past 12 months, compared with -3.81% for ASMB (price return, excluding dividends). Past performance does not predict future results.
Are Assembly Biosciences and Capricor Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.